fashion -WSS

fashion

author：hotspot 2025-09-30 18:43:09 - browse：7

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： In Spain, a hospital brews its own CAR

WSS

Virtual care provider acquires bankrupt Pear's prescription apps

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

House looks to weaken Medicare negotiation

entertainment

fashion

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

In search for therapies for solid tumors, companies turn to claudin

How to save PrEP access — and even expand it

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Jerome Adams on the need for new antivirals for Covid

Bristol Myers buys into radiopharmaceuticals with RayzeBio

ChatGPT in medicine: STAT answers readers' burning questions

Grail spinoff by Illumina should end disastrous merger attempt

Sports medicine is finally prioritizing gender equality

A Q&A with Aletha Maybank, AMA’s chief health equity officer

explore

HCA sued by state AG for quality issues at Mission Health

RaDonda Vaught to speak at CommonSpirit event on patient safety

Why health records don't always know when patients are dead

An inside look at PIPEs, biotech's buzzy new financing tool

An inside look at PIPEs, biotech's buzzy new financing tool

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

knowledge

focus

focus

focus